The Shareholders Foundation announced that an investigation on behalf of investors of GlobeImmune Inc (NASDAQ:GBIM) shares was launched over potential securities laws violations by GlobeImmune and certain of its directors and officers.
Investors who purchased shares of GlobeImmune Inc (NASDAQ:GBIM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of GlobeImmune Inc (NASDAQ:GBIM) concerning whether a series of statements by GlobeImmune regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 27, 2015, GlobeImmune Inc announced top line results from the Phase 2 trial for its hepatitis B treatment.
On June 10, 2015, GlobeImmune Inc announced that, “it is evaluating strategic options for the company. In conjunction with this process, the Board has authorized eliminating the majority of positions in its workforce. . . Following our recent data announcement in our hepatitis B program, this workforce reduction is a necessary action to conserve working capital and provide maximum flexibility in determining the future direction of GlobeImmune.” Shares of GlobeImmune Inc (NASDAQ:GBIM) declined to as low as $2.50 per share on June 29, 2015.
Those who purchased shares of GlobeImmune Inc (NASDAQ:GBIM) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com